Find Florida: 2016

Wednesday, September 28, 2016

Trental

Trental is a brand name of pentoxifylline, approved by the FDA in the following formulation(s):

TRENTAL (pentoxifylline - tablet, extended release; oral)

Manufacturer: SANOFI AVENTIS US

Approval date: August 30, 1984

Strength(s): 400MG ^[RLD]^[AB]

Has a generic version of Trental been approved?

Yes. The following products are equivalent to Trental:

pentoxifylline tablet, extended release; oral

Manufacturer: APOTEX

Approval date: June 9, 1999

Strength(s): 400MG ^[AB]

Manufacturer: IMPAX LABS

Approval date: August 10, 1999

Strength(s): 400MG ^[AB]

Manufacturer: MYLAN

Approval date: July 8, 1997

Strength(s): 400MG ^[AB]

Manufacturer: PLIVA

Approval date: May 25, 1999

Strength(s): 400MG ^[AB]

Manufacturer: VALEANT INTL

Approval date: July 20, 1998

Strength(s): 400MG ^[AB]

Manufacturer: WATSON LABS

Approval date: September 4, 1998

Strength(s): 400MG ^[AB]

PENTOXIL (pentoxifylline tablet, extended release; oral)

Manufacturer: UPSHER SMITH

Approval date: March 31, 1999

Strength(s): 400MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trental. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Trental.

Has a generic version of Tradjenta been approved?

No. There is currently no therapeutically equivalent version of Tradjenta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tradjenta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Patent 6,303,661
Issued: October 16, 2001
Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
Assignee(s): Probiodrug
Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
Patent expiration dates:
- April 24, 2017
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR

Method of regulating glucose metabolism, and reagents related thereto
Patent 6,890,898
Issued: May 10, 2005
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
1149336 Ontario Inc.
New England Medical Center Hospitals, Inc.
The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
Patent expiration dates:
- February 2, 2019
  ✓
  Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Method of regulating glucose metabolism, and reagents related thereto
Patent 7,078,381
Issued: July 18, 2006
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
Patent expiration dates:
- February 2, 2019
  ✓
  Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 7,407,955
Issued: August 5, 2008
Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf R. H. & Tadayyon; Mohammad
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Patent expiration dates:
- August 12, 2023
  ✓
  Drug substance
  ✓
  Drug product

Method of regulating glucose metabolism, and reagents related thereto
Patent 7,459,428
Issued: December 2, 2008
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
New England Medical Center Hospitals, Inc.
1149336 Ontario, Inc.
One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
Patent expiration dates:
- February 2, 2019
  ✓
  Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- May 2, 2016 - NEW CHEMICAL ENTITY

Has a generic version of Vimovo been approved?

No. There is currently no therapeutically equivalent version of Vimovo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vimovo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions
Patent 5,714,504
Issued: February 3, 1998
Inventor(s): Lindberg; Per Lennart & Von Unge; Sverker
Assignee(s): Astra Aktiebolag
The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H- benzimidazole or (-)-5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Patent expiration dates:
- February 3, 2015
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug product
- August 3, 2015
  ✓
  Pediatric exclusivity

Omeprazole magnesium salt form
Patent 5,900,424
Issued: May 4, 1999
Inventor(s): Kallstrom; Lars .ANG.ke & Nygren; Monica Annelie
Assignee(s): Astra Aktiebolag
A novel compound form of magnesium omeprazole useful in the manufacture of pharmaceutical formulations, the use of the product and the process for its production are described.
Patent expiration dates:
- May 4, 2016
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug substance
- November 4, 2016
  ✓
  Pediatric exclusivity

Form of S-omeprazole
Patent 6,369,085
Issued: April 9, 2002
Inventor(s): Hanna; Cotton & Anders; Kronström & Anders; Mattson & Eva; Möller
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Patent expiration dates:
- May 25, 2018
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug substance
  ✓
  Drug product
- November 25, 2018
  ✓
  Pediatric exclusivity

Compounds
Patent 6,875,872
Issued: April 5, 2005
Inventor(s): Lindberg; Per Lennart & Von Unge; Sverker
Assignee(s): AstraZeneca
The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Patent expiration dates:
- May 27, 2014
  ✓
  Drug substance
- November 27, 2014
  ✓
  Pediatric exclusivity

Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent 6,926,907
Issued: August 9, 2005
Inventor(s): Plachetka; John R.
Assignee(s): Pozen Inc.
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Patent expiration dates:
- February 28, 2023
  ✓
  Patent use: RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug product

Form of S-omeprazole
Patent 7,411,070
Issued: August 12, 2008
Inventor(s): Cotton; Hanna & Kronström; Anders & Mattson; Anders & Möller; Eva
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Patent expiration dates:
- May 25, 2018
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug substance
- November 25, 2018
  ✓
  Pediatric exclusivity

Form of S-omeprazole
Patent 7,745,466
Issued: June 29, 2010
Inventor(s): Cotton; Hanna & Kronström; Anders & Mattson; Anders & Möller; Eva
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Patent expiration dates:
- October 13, 2018
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- April 30, 2013 - NEW COMBINATION

Has a generic version of Viramune been approved?

No. There is currently no therapeutically equivalent version of Viramune available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viramune. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
Patent 5,366,972
Issued: November 22, 1994
Inventor(s): Hargrave; Karl D. & Proudfoot; John R. & Adams; Julian & Grozinger; Karl G. & Schmidt, deceased; Gunther & Engel; Wolfhard & Trummlitz; Gunther & Eberlein; Wolfgang
Assignee(s): Boehringer Ingelheim Pharmaceuticals, Inc.
Disclosed are novel 5,11-dihydro-6H-dipyrido[3,2-b; 2',3'-e][1,4]diazepines. These are useful in the prevention or treatment of HIV infection.
Patent expiration dates:
- November 22, 2011
  ✓
  Patent use: METHOD FOR TREATING HIV-1 INFECTION
- November 22, 2011
- May 22, 2012
  ✓
  Pediatric exclusivity

Has a generic version of Promacta been approved?

No. There is currently no therapeutically equivalent version of Promacta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Promacta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Metal complexes
Patent 6,280,959
Issued: August 28, 2001
Inventor(s): Gleason; John G. & Luengo; Juan I.
Assignee(s): SmithKline Beecham Corporation
The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.
Patent expiration dates:
- October 30, 2018
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug substance
  ✓
  Drug product

Thrombopoietin mimetics
Patent 7,160,870
Issued: January 9, 2007
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I. & Visonneau; Sophie
Assignee(s): SmithKline Beecham Corporation
Glaxo Group Limited
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- December 8, 2021
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug substance
  ✓
  Drug product

Thrombopoietin mimetics
Patent 7,332,481
Issued: February 19, 2008
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan & Price; Alan T. & Shaw; Antony N. & Visonneau; Sophie & Wiggall; Kenneth
Assignee(s): SmithKline Beecham Corporation
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- May 24, 2021
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

Thrombopoietin mimetics
Patent 7,452,874
Issued: November 18, 2008
Inventor(s): Duffy; Kevin J. & Luengo; Juan I. & Shaw; Antony N. & Wiggall; Kenneth
Assignee(s): SmithKline Beecham Corp.
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- May 24, 2021
  ✓
  Drug substance
  ✓
  Drug product

Thrombopoietin mimetics
Patent 7,473,686
Issued: January 6, 2009
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I. & Visonneau; Sophie
Assignee(s): SmithKline Beecham Corp.
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- May 24, 2021
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug substance
  ✓
  Drug product

3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Patent 7,547,719
Issued: June 16, 2009
Inventor(s): Moore; Stephen
Assignee(s): SmithKline Beecham Corp.
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid.
Patent expiration dates:
- July 13, 2025
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug substance
  ✓
  Drug product

Thrombopoietin mimetics
Patent 7,790,704
Issued: September 7, 2010
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I.
Assignee(s): GlaxoSmithKline, LLC
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- May 24, 2021
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 7,795,293
Issued: September 14, 2010
Inventor(s): Moore; Stephen
Assignee(s): GlaxoSmithKline LLC
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid.
Patent expiration dates:
- May 21, 2023
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,052,993
Issued: November 8, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Patent expiration dates:
- August 1, 2027
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug product

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,052,994
Issued: November 8, 2011
Inventor(s): Muller; Francis X. & Kapsi; Shivakumar G.
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Patent expiration dates:
- August 1, 2027
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug product

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,062,665
Issued: November 22, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Patent expiration dates:
- August 1, 2027
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug product

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,071,129
Issued: December 6, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Patent expiration dates:
- August 1, 2027
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- November 20, 2013 - NEW CHEMICAL ENTITY
- November 20, 2015 - ORPHAN DRUG EXCLUSIVITY

Tuesday, September 27, 2016

Viagra

Viagra is a brand name of sildenafil, approved by the FDA in the following formulation(s):

VIAGRA (sildenafil citrate - tablet; oral)

Manufacturer: PFIZER IRELAND

Approval date: March 27, 1998

Strength(s): EQ 100MG BASE ^[RLD], EQ 25MG BASE, EQ 50MG BASE

Has a generic version of Viagra been approved?

No. There is currently no therapeutically equivalent version of Viagra available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viagra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pyrazolopyrimidinone antianginal agents
Patent 5,250,534
Issued: October 5, 1993
Inventor(s): Bell; Andrew S. & Brown; David & Terrett; Nicholas K.
Assignee(s): Pfizer Inc.
Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 - C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
Patent expiration dates:
- March 27, 2012
- September 27, 2012
  ✓
  Pediatric exclusivity

Pyrazolopyrimidinones for the treatment of impotence
Patent 6,469,012
Issued: October 22, 2002
Inventor(s): Peter; Ellis & Nicholas Kenneth; Terrett
Assignee(s): Pfizer Inc
The use of a compound of formula (I) wherein R1 is H; C1-C3 alkyl; C1-C3 perfluoroalkyl; or C3-C5 cycloalkyl; R2 is H; optionally substituted C1-C6 alkyl; C1-C3 perfluoroalkyl; or C3-C6 cycloalkyl; R3 is optionally substituted C1-C6 alkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R4 is optionally substituted C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkanoyl, (hydroxy)C2-C4 alkyl or (C2-C3 alkoxy)C1-C2 alkyl; CONR5R6; CO2R7; halo; NR5R6; NHSO2NR5R6; NHSO2R8; SO2NR9R10; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R11)-piperazinyl or imidazolyl group; R7 is H or C1-C4 alkyl; R8 is optionally substituted C1-C3 alkyl; R9 and R10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R12)-piperazinyl group; R11 is H; optionally substituted C1-C3 alkyl; (hydroxy)C2-C3 alkyl; or C1-C4 alkanoyl; R12 is H; optionally substituted C1-C6 alkyl; CONR13R14; CSNR13R14; or C(NH)NR13R14; and R&quest;13&quest; and R14 are each independently H; C1-C4 alkyl; or substituted C2-C4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.
Patent expiration dates:
- October 22, 2019
  ✓
  Patent use: TREATMENT OF ERECTILE DYSFUNCTION
- April 22, 2020
  ✓
  Pediatric exclusivity

Has a generic version of Arestin been approved?

No. There is currently no therapeutically equivalent version of Arestin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arestin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Arestin.

Has a generic version of Ditropan been approved?

Yes. The following products are equivalent to Ditropan:

oxybutynin chloride tablet; oral

Manufacturer: PLIVA

Approval date: November 14, 1988

Strength(s): 5MG ^[AB]

Manufacturer: USL PHARMA

Approval date: July 31, 1996

Strength(s): 5MG ^[AB]

Manufacturer: VINTAGE PHARMS

Approval date: October 31, 1997

Strength(s): 5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ditropan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ditropan.

Has a generic version of Invega Sustenna been approved?

No. There is currently no therapeutically equivalent version of Invega Sustenna available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invega Sustenna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

3-piperidinyl-1,2-benzisoxazoles
Patent 5,254,556
Issued: October 19, 1993
Inventor(s): Janssen; Cornelus G. M. & Knaeps; Alfonsus G. & Kennis; Ludo E. J. & Vandenberk; Jan
Assignee(s): Janssen Pharmaceutica N.V.
The invention relates to C.sub.2-20 alkanoic acid esters of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6, 7,8,9-tetrahydro-9-hydroxy-2 -methyl-4H-pyrido[1,2-a]pyrimidin-4-one, pharmaceutically acceptable acid addition salts thereof, and enantiomeric forms thereof, which are useful in the treatment of warm-blooded animals suffering from psychotic diseases.
Patent expiration dates:
- October 27, 2012
  ✓
  Patent use: TREATMENT OF SCHIZOPHRENIA
  ✓
  Drug substance
  ✓
  Drug product
- April 27, 2013
  ✓
  Pediatric exclusivity

Use of purified surface modifiers to prevent particle aggregation during sterilization
Patent 5,352,459
Issued: October 4, 1994
Inventor(s): Hollister; Kenneth R. & Ladd; David & McIntire; Gregory L. & Na; George C. & Rajagopalan; Natarajan & Yuan; Barbara O.
Assignee(s): Sterling Winthrop Inc.
This invention discloses a composition comprised of nanoparticles having a purified polymeric surfactant as a surface modifier adsorbed on the surface thereof and a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the cloud point of the surface modifier. Preferred purified polymeric surfactants are purified polyalkyleneoxide substituted ethylenediamine surfactants. A preferred cloud point modifier is polyethylene glycol. This invention further discloses a method of making nanoparticles having a purified polymeric surfactant as a surface modifier adsorbed on the surface and a cloud point modifier associated therewith, comprised of contacting said nanoparticles with the cloud point modifier for a time and under conditions sufficient to increase the cloud point of the surface modifier.
Patent expiration dates:
- December 16, 2012
  ✓
  Drug product
- June 16, 2013
  ✓
  Pediatric exclusivity

Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
Patent 6,077,843
Issued: June 20, 2000
Inventor(s): Fran.cedilla.ois; Marc Karel Jozef & Embrechts; Roger Carolus Augusta & Borghijs; Herman Karel & Monbaliu; Johan
Assignee(s): Janssen Pharmaceutica, N.V.
The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein; and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.
Patent expiration dates:
- May 12, 2017
  ✓
  Patent use: TREATMENT OF SCHIZOPHRENIA
  ✓
  Drug product
- November 12, 2017
  ✓
  Pediatric exclusivity

Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
Patent 6,555,544
Issued: April 29, 2003
Inventor(s): Marc Karel Jozef; François & Willy Maria Albert Carlo; Dries & Esther Dina Guido; Basstanie
Assignee(s): Janssen Pharmaceutica, N.V.
The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxy-risperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof in submicron form and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein: and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of psychosis, schizophrenia, schizoaffective disorders, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, Tourette's syndrome, bipolar mania, depression, anxiety.
Patent expiration dates:
- November 10, 2018
  ✓
  Patent use: TREATMENT OF SCHIZOPHRENIA
  ✓
  Drug product
- May 10, 2019
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- December 19, 2011 - NEW CHEMICAL ENTITY
- June 19, 2012 - PEDIATRIC EXCLUSIVITY
- July 31, 2012 - NEW DOSAGE FORM
- January 31, 2013 - PEDIATRIC EXCLUSIVITY

Has a generic version of Daraprim been approved?

No. There is currently no therapeutically equivalent version of Daraprim available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Daraprim. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Daraprim.

Has a generic version of Depen been approved?

No. There is currently no therapeutically equivalent version of Depen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Depen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Depen.

Has a generic version of Benzamycin Pak been approved?

No. There is currently no therapeutically equivalent version of Benzamycin Pak available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Benzamycin Pak. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Benzamycin Pak.

Has a generic version of Desferal been approved?

Yes. The following products are equivalent to Desferal:

deferoxamine mesylate injectable; injection

Manufacturer: APP PHARMS

Approval date: September 15, 2009

Strength(s): 2GM/VIAL ^[AP], 500MG/VIAL ^[AP]

Manufacturer: BEDFORD

Approval date: May 30, 2007

Strength(s): 2GM/VIAL ^[AP], 500MG/VIAL ^[AP]

Manufacturer: HOSPIRA

Approval date: March 17, 2004

Strength(s): 2GM/VIAL ^[AP], 500MG/VIAL ^[AP]

Manufacturer: WATSON LABS

Approval date: March 31, 2006

Strength(s): 2GM/VIAL ^[AP], 500MG/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Desferal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Desferal.

Has a generic version of Denavir been approved?

No. There is currently no therapeutically equivalent version of Denavir available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Denavir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Treatment of a latent infection of herpes viruses
Patent 5,840,763
Issued: November 24, 1998
Inventor(s): Field; Hugh John & Thackray; Alana Maureen & Bacon; Teresa Helen & Sutton; David & Vere Hodge; Richard Anthony
Assignee(s): SmithKline Beecham plc
A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
Patent expiration dates:
- September 1, 2015
  ✓
  Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

Penciclovir for the treatment of post therapeutic neuralgia
Patent 5,866,581
Issued: February 2, 1999
Inventor(s): Boon; Ronald James & Griffin; David Ronald John
Assignee(s): SmithKline Beecham p.l.c.
A method for the treatment of PHN in mammals, including humans, which method comprises administering an effective amount of a compound of formula (A), or a pharmaceutically acceptable salt thereof. ##STR1##
Patent expiration dates:
- October 4, 2014
  ✓
  Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

Treatment of a latent infection of herpes virus
Patent 5,916,893
Issued: June 29, 1999
Inventor(s): Field; Hugh John & Thackray; Alana Maureen & Bacon; Teresa Helen & Sutton; David & Vere Hodge; Richard Anthony
Assignee(s): SmithKline Beecham p.l.c.
A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
Patent expiration dates:
- September 1, 2015
  ✓
  Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

Penciclovir for the treatment of zoster associated pain
Patent 6,124,304
Issued: September 26, 2000
Inventor(s): Boon; Ronald James & Griffin; David Ronald John
Assignee(s): SmithKline Beecham PLC
A method for the treatment of ZAP, in particular PHN, in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof.
Patent expiration dates:
- October 4, 2014
  ✓
  Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

Pharmaceutical formulation
Patent 6,469,015
Issued: October 22, 2002
Inventor(s): Hazel-Ann; Griffiths & Alan John; Goodall & Joshua; Oduro-Yeboah
Assignee(s): Novartis International Pharmaceutical Ltd
An oil-in-water topical pharmaceutical formulation or an aqueous formulation for the treatment of virus infections of the skin or mucosa, comprising at least 30% of propylene glycol and solubilized penciclovir.
Patent expiration dates:
- October 22, 2019
  ✓
  Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

Antiviral guanine derivatives
Patent 6,579,981
Issued: June 17, 2003
Inventor(s): Richard Lewis; Jarvest & Michael Raymond; Harnden
Assignee(s): Novartis International Pharmaceutical Ltd.
A compound of formula (I) or a salt or acyl derivative thereof, in which X represents chlorine, C1-6 alkoxy, phenoxy, phenyl C1-6 alkoxy, NH2, —OH or —SH, is useful in treating viral infections.
Patent expiration dates:
- June 17, 2020
  ✓
  Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

Has a generic version of Demser been approved?

No. There is currently no therapeutically equivalent version of Demser available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Demser. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Demser.

Has a generic version of Diamox been approved?

Yes. The following products are equivalent to Diamox:

acetazolamide capsule, extended release; oral

Manufacturer: HERITAGE PHARMS INC

Approval date: July 14, 2011

Strength(s): 500MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: December 10, 2008

Strength(s): 500MG ^[AB]

acetazolamide sodium injectable; injection

Manufacturer: BEDFORD

Approval date: February 28, 1995

Strength(s): EQ 500MG BASE/VIAL ^[AP]

Manufacturer: X GEN PHARMS

Approval date: December 10, 2008

Strength(s): EQ 500MG BASE/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Diamox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Diamox.

Has a generic version of Depakote been approved?

A generic version of Depakote has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Depakote and have been approved by the FDA:

divalproex sodium capsule, delayed rel pellets; oral

Manufacturer: DR REDDYS LABS LTD

Approval date: January 23, 2009

Strength(s): EQ 125MG VALPROIC ACID ^[AB]

Manufacturer: MYLAN

Approval date: March 28, 2011

Strength(s): EQ 125MG VALPROIC ACID ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: January 27, 2009

Strength(s): EQ 125MG VALPROIC ACID ^[AB]

divalproex sodium tablet, delayed release; oral

Manufacturer: ANCHEN PHARMS

Approval date: November 3, 2008

Strength(s): EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: AUROBINDO PHARMA LTD

Approval date: April 21, 2011

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: DR REDDYS LABS LTD

Approval date: July 29, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: LUPIN

Approval date: July 29, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: MYLAN

Approval date: July 29, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: MYLAN

Approval date: March 17, 2009

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: NU PHARM

Approval date: July 29, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: ORCHID HLTHCARE

Approval date: November 25, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: SANDOZ

Approval date: July 29, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: July 29, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: TEVA

Approval date: July 29, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: UNICHEM LABS LTD

Approval date: April 5, 2011

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: UPSHER SMITH

Approval date: July 29, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: VINTAGE

Approval date: November 30, 2009

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: WATSON LABS FLORIDA

Approval date: February 25, 2011

Strength(s): EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: WOCKHARDT

Approval date: July 31, 2008

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: March 5, 2009

Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Depakote. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Depakote.

Related Exclusivities

Exclusivity expiration dates:
- March 24, 2011 - EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- September 24, 2011 - PEDIATRIC EXCLUSIVITY

Has a generic version of Aptivus been approved?

No. There is currently no therapeutically equivalent version of Aptivus available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aptivus. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pyranone compounds useful to treat retroviral infections
Patent 5,852,195
Issued: December 22, 1998
Inventor(s): Romines; Karen Rene & Bundy; Gordon L. & Schwartz; Theresa M. & Tommasi; Ruben A. & Strohbach; Joseph W. & Turner; Steven Ronald & Thaisrivongs; Suvit & Aristoff; Paul Adrian & Johnson; Paul D. & Skulnick; Harvey Irving & Skaletzky; Louis L. & Anderson; David John & Morris; Joel
Assignee(s): Pharmacia & Upjohn Company
The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl›b!pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R.sub.10 and R.sub.20 taken together are formulae (III) and (IV). ##STR1##
Patent expiration dates:
- June 22, 2019
  ✓
  Drug substance
- December 22, 2019
  ✓
  Pediatric exclusivity

Method for improving the pharmacokinetics of tipranavir
Patent 6,147,095
Issued: November 14, 2000
Inventor(s): Ferry; James J. & Baldwin; John R. & Borin; Marie T.
Assignee(s): Pharmacia & Upjohn Company
The present invention relates to a novel method for improving the pharmacokinetics of tipranavir, comprising administering to a human in need of such treatment a combination of a therapeutically effective amount of tipranavir or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of ritonavir or a pharmaceutically acceptable salt thereof.
Patent expiration dates:
- October 29, 2019
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
- April 29, 2020
  ✓
  Pediatric exclusivity

Compounds useful to treat retroviral infections
Patent 6,169,181
Issued: January 2, 2001
Inventor(s): Romines; Karen Rene & Bundy; Gordon L. & Schwartz; Theresa M. & Tommasi; Ruben A. & Strohbach; Joseph W. & Turner; Steven Ronald & Thaisrivongs; Suvit & Aristoff; Paul Adrian & Johnson; Paul D. & Skulnick; Harvey Irving & Skaletzky; Louis L. & Anderson; David John & Morris; Joel
Assignee(s): Pharmacia & Upjohn Company
The present invention relates to compounds of formula I and II which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus. ##STR1## wherein R.sub.10 and R.sub.20 taken together are: ##STR2##
Patent expiration dates:
- May 6, 2014
  ✓
  Drug substance
- November 6, 2014
  ✓
  Pediatric exclusivity

Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
Patent 6,231,887
Issued: May 15, 2001
Inventor(s): Gao; Ping & Morozowich; Walter
Assignee(s): Pharmacia & Upjohn Company
The present invention provides a novel pharmaceutical composition based on the use of a particular amount of basic amine which comprises a pyranone compound as a pharmaceutically active agent, a basic amine in an amount of from about 0.1% to about 10% by weight of the total composition, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. In addition, the composition may further comprises one or more pharmaceutically acceptable oils. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic pyranone compounds.
Patent expiration dates:
- July 27, 2018
  ✓
  Drug product
- January 27, 2019
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- December 22, 2010 - PEDIATRIC EXCLUSIVITY
- June 23, 2011 - USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
- December 23, 2011 - PEDIATRIC EXCLUSIVITY

Has a generic version of Dilacor XR been approved?

A generic version of Dilacor XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Dilacor XR and have been approved by the FDA:

diltiazem hydrochloride capsule, extended release; oral

Manufacturer: APOTEX

Approval date: August 6, 1998

Strength(s): 240MG ^[AB2]

Manufacturer: APOTEX

Approval date: December 19, 2000

Strength(s): 120MG ^[AB2], 180MG ^[AB2]

Manufacturer: MYLAN

Approval date: March 18, 1998

Strength(s): 120MG ^[AB2], 180MG ^[AB2], 240MG ^[AB2]

Manufacturer: WATSON LABS FLORIDA

Approval date: October 10, 1997

Strength(s): 120MG ^[AB2], 180MG ^[AB2], 240MG ^[AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dilacor XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Tablets with controlled-rate release of active substances
Patent 5,422,123
Issued: June 6, 1995
Inventor(s): Conte; Ubaldo & La Manna; Aldo & Colombo; Paolo
Assignee(s): Jagotec AG
Tablets with zero order controlled-rate of release of the active substances, consisting of a core of defined geometrical form containing the active substance, polymer substances which swell on contact with aqueous liquids and polymer substances with gelling properties, and a support applied to said core to partly cover its surface, the support consisting of polymer substances which are slowly soluble and/or slowly gellable in aqueous liquids, plasticizing substances, and possibly substances with an adjuvant function.
Patent expiration dates:
- June 6, 2012

Wednesday, September 28, 2016

TRENTAL (pentoxifylline - tablet, extended release; oral)

Has a generic version of Trental been approved?

pentoxifylline tablet, extended release; oral

PENTOXIL (pentoxifylline tablet, extended release; oral)

Related Patents

See also...

TRADJENTA (linagliptin - tablet; oral)

Has a generic version of Tradjenta been approved?

Related Patents

Related Exclusivities

See also...

VIMOVO (esomeprazole magnesium; naproxen - tablet, delayed release; oral)

Has a generic version of Vimovo been approved?

Related Patents

Related Exclusivities

See also...

VIRAMUNE (nevirapine - suspension; oral)

VIRAMUNE (nevirapine - tablet; oral)

Has a generic version of Viramune been approved?

Related Patents

See also...

PROMACTA (eltrombopag olamine - tablet; oral)

Has a generic version of Promacta been approved?

Related Patents

Related Exclusivities

See also...

Tuesday, September 27, 2016

VIAGRA (sildenafil citrate - tablet; oral)

Has a generic version of Viagra been approved?

Related Patents

See also...

ARESTIN (minocycline hydrochloride - powder, extended release; dental)

Has a generic version of Arestin been approved?

Related Patents

See also...

DITROPAN (oxybutynin chloride - tablet; oral)

Has a generic version of Ditropan been approved?

oxybutynin chloride tablet; oral

Related Patents

See also...

INVEGA SUSTENNA (paliperidone palmitate - suspension, extended release; intramuscular)

Has a generic version of Invega Sustenna been approved?

Related Patents

Related Exclusivities

See also...

DARAPRIM (pyrimethamine - tablet; oral)

Has a generic version of Daraprim been approved?

Related Patents

See also...

DEPEN (penicillamine - tablet; oral)

Has a generic version of Depen been approved?

Related Patents

See also...

BENZAMYCIN PAK (benzoyl peroxide; erythromycin - gel; topical)

Has a generic version of Benzamycin Pak been approved?

Related Patents

See also...

DESFERAL (deferoxamine mesylate - injectable; injection)

Has a generic version of Desferal been approved?

deferoxamine mesylate injectable; injection

Related Patents

See also...

DENAVIR (penciclovir sodium - cream; topical)

Has a generic version of Denavir been approved?

Related Patents

See also...

DEMSER (metyrosine - capsule; oral)

Has a generic version of Demser been approved?

Related Patents

See also...

DIAMOX (acetazolamide - capsule, extended release; oral)

DIAMOX (acetazolamide sodium - injectable; injection)

Has a generic version of Diamox been approved?

acetazolamide capsule, extended release; oral

acetazolamide sodium injectable; injection

Related Patents

See also...

DEPAKOTE (divalproex sodium - capsule, delayed rel pellets; oral)

DEPAKOTE (divalproex sodium - tablet, delayed release; oral)